Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years.

Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan AC, Faizal A, Goddard C, Pugh M, Bowman SJ, Brailsford S, Nightingale P.

BMJ Open. 2012 Nov 12;2(6). pii: e001395. doi: 10.1136/bmjopen-2012-001395. Print 2012.

2.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
3.

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.

Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB.

Lancet. 2016 Jul 16;388(10041):239-47. doi: 10.1016/S0140-6736(16)00380-9. Epub 2016 May 17.

PMID:
27197690
4.

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.

van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, den Broeder AA.

BMJ. 2015 Apr 9;350:h1389. doi: 10.1136/bmj.h1389.

5.

Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.

Li N, Betts KA, Messali AJ, Skup M, Garg V.

Clin Ther. 2017 Aug;39(8):1618-1627. doi: 10.1016/j.clinthera.2017.06.009. Epub 2017 Jul 17.

6.

Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.

ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D, Voskuyl AE, Lems WF.

Ann Rheum Dis. 2015 Jun;74(6):1233-40. doi: 10.1136/annrheumdis-2013-205143. Epub 2014 May 12.

PMID:
24818633
7.

Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.

Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.

J Manag Care Spec Pharm. 2014 Jul;20(7):657-67.

8.

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M; All Departments of Rheumatology in Denmark.

Arthritis Rheum. 2010 Jan;62(1):22-32. doi: 10.1002/art.27227.

9.

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study.

den Broeder AA, van Herwaarden N, van der Maas A, van den Hoogen FH, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

BMC Musculoskelet Disord. 2013 Oct 24;14:299. doi: 10.1186/1471-2474-14-299.

10.

Anti-TNF agents for paediatric psoriasis.

Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X.

Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2. Review.

PMID:
26598969
11.

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15.

PMID:
21572150
12.

The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.

Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, Van Oijen PC, Van Riel PC.

Ann Rheum Dis. 2008 Sep;67(9):1229-34. doi: 10.1136/ard.2007.083675. Epub 2008 Jan 3.

PMID:
18174220
13.

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.

Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, Askling J; ARTIS Study Group.

Ann Rheum Dis. 2015 Feb;74(2):354-60. doi: 10.1136/annrheumdis-2013-204128. Epub 2013 Nov 27.

14.

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.

Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K; OPERA Study-Group.

Ann Rheum Dis. 2014 Apr;73(4):654-61. doi: 10.1136/annrheumdis-2012-202735. Epub 2013 Feb 23.

PMID:
23434570
15.

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.

van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Pedersen R, Freundlich B, Fatenejad S.

Ann Rheum Dis. 2006 Mar;65(3):328-34. Epub 2005 Aug 3.

16.

Etanercept for the treatment of rheumatoid arthritis.

Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2013 May 31;(5):CD004525. doi: 10.1002/14651858.CD004525.pub2. Review.

PMID:
23728649
17.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

18.

Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.

Moreland LW.

Pharmacoeconomics. 2004;22(2 Suppl 1):39-53. Review. Erratum in: Pharmacoeconomics. 2004;22(8):547.

PMID:
15157003
20.

Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study.

Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman H, Dormuth CR.

PLoS One. 2014 Aug 20;9(8):e105193. doi: 10.1371/journal.pone.0105193. eCollection 2014.

Supplemental Content

Support Center